DB18625InvestigationalCell transplant therapies
CTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.
- Mechanism
- Curator reviewed
Pharmacologically active on Tumor necrosis factor receptor superfamily member 17
- Also known as
- allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting B-cell maturation antigen
- Code names
- CTX-120
Resolves to
Targets
What you can answer from here — as of July 09, 2026
Which drugs share a target with CTX120, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account